August 12, 2021 11:06 AM 28 seconds read

Allogene's BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma

by Vandana Singh Benzinga Editor
Follow
Comments
  • The FDA has granted Orphan Drug Designation to Allogene Therapeutics Inc's ALLO ALLO-715 to treat multiple myeloma.
  • In April 2021, ALLO-715 received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA.
  • ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), is a potential novel treatment for multiple myeloma and other BCMA-positive malignancies.
  • Price Action: ALLO shares are down 2.35% at $20.75 during the market session on the last check Thursday.
  • Related content: Benzinga's Full FDA Calendar.
ALLO Logo
ALLOAllogene Therapeutics Inc
$2.03-%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum12.06
Growth99.35
Quality-
Value0.26
Price Trend
Short
Medium
Long
Overview
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:
BiotechNewsHealth CareFDAGeneralBriefsmultiple myelomaOrphan Drug Designation

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved